The Act organises a compact set of statutory concepts that drive how the Institute operates and how it interacts with government, health providers, research bodies and the public.

Cancer Institute as a corporate entity

• The Act creates a corporation named the Cancer Institute (NSW) that does not represent the Crown (s 4(1)-(2)). This means the Institute is a statutory corporation with corporate capacity, but the Act expressly separates it from being the Crown.

Objectives and guiding principles

• The Institute’s objects are specific and outcome-oriented: increase survival, reduce incidence, improve quality of life, and operate as a source of expertise (s 5). The guiding principles require partnership across sectors, equitable evidence-based care, accountability for public funds used for new activities, and public availability of up-to-date information, among other points (s 6). The Act sets these as principles to be “had regard to” when exercising functions (s 6).

Functions and scope of “cancer control”

• The statutory definition of “cancer control” is broad, explicitly including research, treatment, palliative and supportive care, prevention, screening, diagnosis, information provision, training and complementary therapies (s 3). The Institute’s functions mirror that breadth: research commissioning, facilitating ethical approval for multicentre trials, accrediting programs, reviewing public-system programs, developing a State Cancer Plan (s 12).

Governance architecture

• A Board governs the Institute and is subject to Ministerial control and direction, except in relation to a report or recommendation the Board makes to the Minister (s 7(1)-(4)). Board membership consists of between five and eleven Minister-appointed persons plus the Chief Cancer Officer (s 8). The Board must establish specified advisory committees (ethics, clinical services, research, quality and clinical effectiveness) and may create others (s 9).

Chief Cancer Officer and executive management

• The Chief Cancer Officer is the Institute’s chief executive and is on the Board (s 10(1)-(4)). Whether the appointment and employment rules are governed by the Health Services Act 1997 depends on whether the role is classed as an executive position under that Act; if not, the Minister appoints and the Chief Cancer Officer is employed under Part 1 of Chapter 9 of the Health Services Act while holding office (s 10(2)-(2A), (3)-(4)).

Ministerial powers and administrative finality

• The Governor (effectively the Executive) can remove any member or all members at any time, for any reason or no reason, and can appoint an administrator to exercise Board functions, with remuneration set by the Minister (s 11(1)-(4)). Schedule 2 contains an explicit non-justiciability provision for the Minister’s registration order in relation to the Cancer Council (sch 2 cl 3(4)-(5)).

Powers related to property, gifts and finances

• The Institute can acquire, dispose of and deal in land and property for its functions, but acquisitions or disposals of land require Ministerial approval (s 15). The Institute may accept gifts and bequests and may agree to and carry out conditions attached to them; certain trusts and securities provisions are addressed (s 16). Investment powers are governed by the Government Sector Finance Act if the Institute is a GSF agency; otherwise investments must be authorised for trust funds or by Minister/Treasurer concurrence (s 18).

Information, reporting and interaction with public health bodies

• The Institute may request cancer-control information from any person or body; but where the request is to the Ministry of Health or a public health organisation, the request must be complied with only if the Secretary consents (s 13). Annual reporting to the Minister is mandatory and must be tabled in Parliament by the Minister (s 14).

Delegation, by-laws and staff

• The Institute may make by-laws with Ministerial approval for Board procedures (s 19). It may delegate functions to members of staff (s 20), but the Act elsewhere provides that the Institute cannot itself employ staff directly; staff may be employed under Chapter 9 of the Health Services Act to enable the Institute to exercise its functions (s 12(4) note). Schedule 1 sets procedural rules for Board members including conflict disclosure and vacation of office rules.

Interaction with other statutes

• The Act expressly links to and incorporates provisions from other statutes: Health Services Act 1997 (employment regimes and Chapter 10 administration) and the Corporations Act (for the Cancer Council conversion under sch 2). Section 21A makes Chapter 10 of the Health Services Act extend to the Institute as if it were a statutory health corporation, and that Chapter prevails over the Act to the extent of inconsistency (s 21A).

Legal protections and procedural restrictions

• The statute shields persons acting in good faith executing the Act from personal liability (s 22). It also empowers the Governor and the Minister to issue directions, to remove members and to approve or disapprove land transactions and by-laws, thereby centralising several key decision points in the executive.

These concepts determine the flows of authority, information and resources under the Act, and will govern how the Institute engages with researchers, health services, funders, patients and the wider community.

The Act touches a broad set of public and private actors. The statutory text itself identifies the key affected parties and the mechanisms through which they are affected.

Government actors

• Minister for Health: appoints Board members (s 8(1)(a)), may give directions to the Institute concerning delegations (s 20(2)), approves by-laws (s 19(1)), approves land transactions (s 15(2)), and receives annual reports to be tabled in Parliament (s 14). The Minister also specifies the registration date for the Cancer Council company under sch 2 cl 3 and may repeal the 1995 Cancer Council Act after the registration date (s 27).
• Governor (Executive): may remove members and appoint an administrator and publish orders in the Gazette (s 11(1)).
• Secretary of the Ministry of Health: defined in s 3; the Secretary’s consent is required before the Institute’s requests for information from the Ministry or public health organisations must be complied with (s 13(2)). The Institute is required to advise the Secretary and to undertake assessments as requested by the Minister or Secretary (s 12(j), (k), (l)).

Board and Institute personnel

• Board members, including the Chief Cancer Officer: subject to appointment, remuneration, removal (s 8, sch 1 cl 5-6). Board members must disclose conflicts of interest and may be excused from participation in decisions where conflicts arise (sch 1 cl 8).
• Chief Cancer Officer: the chief executive and ex officio Board member, with management responsibility subject to Board direction (s 10). Employment terms depend on classification under the Health Services Act (s 10(2)-(2A)).

Public health organisations and the NSW Health Service

• The Institute’s powers and functions are often exercised in conjunction with public health organisations; requests for information are subject to Secretary consent (s 13). Chapter 10 of the Health Services Act 1997 extends to the Institute as if it were a statutory health corporation (s 21A), with that Chapter prevailing to the extent of inconsistency (s 21A(2)). Staff who enable the Institute to exercise functions are to be employed under the Health Services Act structure (s 12(4) note; sch 3 Part 2 cl 2).

Researchers, clinicians and trial sponsors

• The Institute is empowered to facilitate expeditious ethical approval for multi-centre clinical trials and other cancer-related research, and to undertake, commission or sponsor research (s 12(2)(a)-(c)). Those conducting research will be affected by the Institute’s ethical approval mechanisms, registers of research bodies (s 12(2)(b)), and accreditation functions (s 12(2)(e)).

Patients, carers and consumers

• The Institute’s objects and guiding principles (ss 5-6) place emphasis on patient-centred care, accessibility irrespective of geographic location, and improved quality of life (s 6(d), (h)). Patients and carers will be affected through changes to public programs, clinical practice guidelines, and the dissemination of information and training (s 12(2)(d), (n), (o), (p)).

Third-party fundraisers, donors and philanthropy

• The Institute may engage in fundraising and must keep publicly available registers of fundraisers (s 12(2)(r); s 6(h) requires information about cancer-related philanthropic activities to be publicly available). The Duties Act exemption for gifts and bequests to the Institute is explicit (s 16(4)), which affects donors’ transactional costs.

Property counterparties and investment counterparties

• Parties to property transactions with the Institute will be affected by Ministerial approval requirements for acquisition or disposal of land (s 15(2)-(4)). Investment intermediaries will engage under the investment regime applicable to the Institute which varies depending on GSF agency status (s 18(1)).

The New South Wales Cancer Council and corporate regulators

• The Cancer Council is a specified entity in sch 2. The Act treats the Cancer Council as a deemed registration company under the Corporations Act from the registration date specified by the Minister (sch 2 cl 2-4). ASIC is required to be provided with a copy of the Minister’s order (sch 2 cl 3(3)). The 1995 Cancer Council Act ceases to apply to the Cancer Council company on and after the registration date (sch 2 cl 5).

Other affected parties and users of Institute records

• Persons whose information is recorded in the Institute’s registers or records will be affected by the Institute’s data collection and public dissemination functions (s 12(2)(b), (r), (n)). The Institute is authorised to request information, subject in some cases to Secretary consent (s 13).

Collectively, the Act establishes administrative interfaces between the Institute and central government, health services, researchers, donors, patients, and public stakeholders, with the statutory text defining where consent, approval or direction is needed and identifying which actors have decision-making authority.

This section pulls out the principal statutory duties the Act places on the Institute, the Board and others, together with rights the Act confers. Each item is grounded in the statutory provisions.

Duties of the Cancer Institute and the Board

• Exercise functions to give effect to objects: the Institute must perform acts and things necessary or convenient to give effect to its objectives (s 12(1)). Those objectives are to increase survival, reduce incidence, improve quality of life and operate as a source of expertise (s 5).
• Perform specified functions: the Institute has a list of enumerated functions including research, facilitating ethical approval processes, accreditation, review and monitoring of public health programs, development of a State Cancer Plan, advising on expenditure of designated appropriations, information collection and dissemination, training and fundraising (s 12(2)(a)-(s)).
• Report annually: required to report to the Minister within four months of the end of each financial year and the Minister must table each report in both Houses within one month after receiving it (s 14(1), (3)-(4)). Reports must include outcomes from initiatives, trends in incidence and survival, and an overview of cancer-related research and philanthropic activities (s 14(3)(a)-(c)).

Duties of the Chief Cancer Officer

• Management subject to Board directions: the Chief Cancer Officer is responsible for managing the Institute’s affairs, subject to and in accordance with any directions of the Board (s 10(4)(a)). The Chief Cancer Officer also has other statutory functions as conferred by this or any other Act (s 10(4)(b)).
• Appointment/employment compliance: appointment and employment may be governed by provisions of the Health Services Act if the position is an executive position under that Act; otherwise appointment is by Minister and employment under the Health Services Act for the duration of office (s 10(2)-(2A)).

Ministerial and Governor powers/duties

• Minister control: the Board is subject to the control and direction of the Minister, except in relation to a report or recommendation made by the Board to the Minister (s 7(4)). The Minister may give directions concerning delegations (s 20(2)).
• Approval gates: Ministerial approval is required for land acquisitions/disposals (s 15(2)) and for by-laws (by-law making requires Minister approval, s 19(1)). The Minister may specify registration dates and make unreviewable orders under sch 2 cl 3(1)-(4).
• Remuneration: the Minister determines remuneration for administrators and Board members (s 11(4); sch 1 cl 5).

Rights conferred on the Institute and Board

• Corporate capacity and contracting: the Institute is a corporation that may enter contracts and the contracts are treated as contracts for or on account of the Public Service of NSW for the purposes of the Constitution Act (s 4(1); s 17(1)-(2)).
• Property powers: right to acquire, dispose of, lease, mortgage and otherwise deal with land and property for functional purposes, subject to Ministerial approval requirements for land (s 15(1)-(2)). The Institute can request Minister approval to override Crown grant trusts or forfeiture consequences (s 15(3)-(4)).
• Acceptance of gifts and securities: power to accept gifts, devises and bequests and to agree to associated conditions; specific rules for retaining securities and participating in issues are provided (s 16(1)-(3)). The Duties Act does not apply to gifts/bequests to the Institute (s 16(4)).
• Investment powers: the Institute may invest held money according to the Government Sector Finance Act if a GSF agency, otherwise in trust-authorised ways or as approved by Minister/Treasurer (s 18(1)).
• Make by-laws, delegate functions: power to make by-laws with Minister approval (s 19(1)) and to delegate functions to members of staff (s 20(1)), subject to limits (cannot delegate power to make by-laws or the power of delegation itself, s 20(1)(a)-(b)).

Procedural and participatory duties on Board members

• Conflict disclosure and non-participation: a member with a direct or indirect pecuniary or other interest must disclose it at a meeting, particulars of disclosure must be recorded, and the member must not be present or take part in deliberations or decisions unless the Minister or Board otherwise determines (sch 1 cl 8(1)-(5)).
• Attendance and office vacancy rules: an appointed member’s office becomes vacant on death, non-reappointment, resignation, prescribed absences from meetings, bankruptcy, conviction of serious offences, mental incapacity, or removal by the Minister (sch 1 cl 6(1)-(2)).

Limits on rights and duties and special provisions

• Information requests to Ministry/public health organisations require Secretary consent before the Institute’s request must be complied with (s 13(2)). This imposes a duty on information-holders only when consent is given and places a practical control in the hands of the Secretary.
• The Institute cannot employ staff directly under the Act (s 12(4)), but the Act contemplates that staff enabling the Institute to exercise functions will be employed under the Health Services Act; delegation to “members of staff of the Cancer Institute” presumes staff will be in place under those other statutory arrangements (s 12(4) note; s 20(1)).

Immunities

• Persons acting in good faith under the Act (Institute, staff, Board, committee members, or persons acting under Board direction) are protected from personal liability for acts or omissions in good faith for the purposes of executing the Act (s 22). This is a statutory good-faith immunity for civil liability.

These duties and rights create a framework in which the Institute operates with corporate powers to contract, acquire property, invest, accept gifts and perform a range of cancer control functions, while centralising certain controls with the Minister and embedding procedural obligations for governance and reporting.

The Act primarily establishes administrative powers, controls and immunities rather than an enforcement regime of criminal sanctions. The statutory text provides mechanisms of executive control, finality for specific orders, and procedural protections; it does not create express fines or criminal offences within the excerpt provided.

Administrative controls and removal powers

• Governor/Minister removal and appointment of administrators: the Governor may remove any member, including the Chief Cancer Officer, or all members at any time for any reason or no reason and appoint an administrator to exercise Board functions (s 11(1)(a)-(c), (3)). The Minister sets administrator remuneration (s 11(4)). The Minister may also remove appointed members at any time without notice under Schedule 1 cl 6(2). These provisions are administrative levers available to government to enforce policy or restructure governance, rather than civil or criminal penalties.

Finality and non-justiciability

• Schedule 2 cl 3(4) provides that an order by the Minister specifying the Cancer Council’s registration date cannot be challenged, reviewed or called into question in any proceedings before any court or tribunal; and cl 3(5) declares such an order to be conclusive evidence that statutory requirements have been complied with. This is an express statutory bar on judicial review in relation to that decision (sch 2 cl 3(4)-(5)).

Civil liability and immunities

• The Act grants statutory protection against personal civil action for persons acting in good faith for the purposes of executing the Act (s 22). That provision limits exposure to personal liability arising from acts or omissions done in good faith, which, in practical terms, reduces the scope for enforcement via personal tort claims against Board members, staff or persons acting under Board direction.

Ministerial approval as an enforcement/control mechanism

• Ministerial approval requirements function as regulatory constraints. Examples:
  • Land acquisition/disposal requires Minister approval (s 15(2)).
  • By-laws require Minister approval (s 19(1)).
  • The Institute’s requests for information from the Ministry of Health or public health organisations are only to be complied with if the Secretary consents (s 13(2)). These approval gates enable the Minister or Secretary to enforce compliance or block certain actions administratively.

Reporting and parliamentary scrutiny

• The Act requires an annual report to be provided to the Minister and tabled in Parliament (s 14(1), (4)). Parliamentary tabling is a public, political enforcement channel where scrutiny and accountability occur through legislative processes rather than through statutory penalty.

Regulations and delegated enforcement

• The Governor may make regulations for matters necessary or convenient for carrying out the Act (s 25(1)). Regulations may contain savings or transitional provisions (sch 3 cl 1). The Act does not specify penalties; however regulations made under s 25 could, in principle, create offences or penalties if authorised by the Act and consistent with its purpose, but no such regulations are set out in the provided text.

Limits on civil remedy for decisions

• Clause sch 1 cl 6(2) gives the Minister power to remove an appointed member from office at any time for any or no reason and without notice. While not a penalty in the criminal sense, removal is a serious administrative consequence. The Act also expressly states an appointed member is not entitled to compensation for removal or non-reappointment (sch 1 cl 10).

Scope of enforcement in the Act

• The Act’s enforcement architecture is predominantly administrative: appointment/removal powers, Ministerial approvals, delegation controls, reporting obligations, and statutory finality for specified Ministerial acts. It contains immunity from personal liability for good-faith acts. The Act does not create detailed statutory enforcement mechanisms such as infringement notices, pecuniary penalties or criminal offences in the text provided.

Where users of the statute may expect enforcement in practice

• Compliance is likely to be driven by political and contractual levers (Ministerial direction, funding controls, approval powers for land and by-laws, contractual remedies under commercial contracts entered by the Institute) and by public accountability through annual reporting and parliamentary tabling. For some acts (e.g., failure by a public health organisation to comply with an information request absent Secretary consent), the statute places substantive limits rather than enforcement pathways,enforcement would depend on the consent process and administrative directions.

The Act cross-references and integrates with multiple other NSW and Commonwealth statutes. These interactions determine employment arrangements, investment rules, corporate status of another entity, and administrative precedence.

Health Services Act 1997

• Definitions: “public health organisation” and “public health system” have the same meanings as in the Health Services Act 1997, which anchors terms used in the Cancer Institute Act (s 3(1)).
• Employment and appointment of Chief Cancer Officer: whether the Chief Cancer Officer’s appointment and employment are governed by Part 3 of Chapter 9 of the Health Services Act depends on whether the position is an “executive position” under that Act. If it is, appointment/employment are subject to that Part; if it is not, the Minister appoints and the Chief Cancer Officer is employed under Part 1 of Chapter 9 while in office (s 10(2)-(2A)). The Act therefore defers to the Health Services Act classification in relation to executive employment conditions.
• Staff employment and administrative provisions: the Act states the Institute cannot employ staff directly, but staff may be employed under Chapter 9 of the Health Services Act to enable the Institute to exercise its functions (s 12(4) note). Additionally, s 21A extends Chapter 10 (Administration of the public health system) of the Health Services Act to the Institute as if it were a statutory health corporation, and that Chapter prevails over the Cancer Institute Act to the extent of inconsistency (s 21A(1)-(2)). This makes the Health Services Act the operative administrative framework for certain Institute functions and administration where overlap exists.

Government Sector Finance Act 2018

• Investments: if the Institute is a GSF agency for the purposes of Part 6 of the Government Sector Finance Act 2018, then investments must be made in accordance with that Part. If not, investments are limited to ways authorised for trust funds or as approved by the Minister with Treasurer concurrence (s 18(1)). This ties financial governance to the State’s government-sector investment rules when the Institute is designated a GSF agency.

Corporations Act 2001 (Commonwealth)

• Cancer Council conversion: sch 2 implements a deemed registration under section 5H of the Corporations Act, specifying the registration date, type of company (company limited by guarantee) and proposed name for The Cancer Council NSW (sch 2 cl 2). The Minister must be satisfied section 5H(2) and (3) of the Corporations Act have been complied with before making the registration order (sch 2 cl 3(2)). The Minister is to provide ASIC with a copy of the order (sch 2 cl 3(3)). The sch 2 cl 3(4)-(5) language creates finality and conclusive evidence for the registration process , effectively integrating the corporate conversion into Corporations Act processes while insulating the Minister’s order from judicial challenge in specified respects.

Duties Act 1997

• Exemption for gifts/bequests: the Act expressly states the Duties Act 1997 does not apply to or in respect of any gift to, or bequest or devise in favour of, the Cancer Institute (s 16(4)). This creates a tax/transfer-duty exemption for donors and affects the costs of charitable giving to the Institute.

Constitution Act 1902

• Contracts entered into by the Institute are taken, for the purposes of the Constitution Act 1902, to be contracts for or on account of the Public Service of New South Wales (s 17(2)). This affects constitutional implications related to public service contracting and may interact with procurement rules in other statutes.

Government Sector Employment Act 2013 and other employment statutes

• Schedule 1 cl 9(1) excludes the provisions of the Government Sector Employment Act 2013 relating to employment of Public Service employees from applying to an appointed member (sch 1 cl 9(1)). Other savings/transitional clauses reference the Public Sector Employment and Management Act 2002 in respect of staff transfers that occurred on earlier amendments (sch 3 Part 2 cl 2). The Act therefore places Board appointment and member employment relationships in a distinct statutory category.

Regulations and subordinate instruments

• The Governor may make regulations consistent with the Act (s 25(1)) and the regulations may contain transitional or savings provisions consequent on the Act’s enactment or later amendments (sch 3 cl 1). Regulations can therefore supplement the Act but must be consistent with it.

Judicial review and finality clauses

• Schedule 2 cl 3(4) creates an explicit statutory bar on judicial challenge to the Minister’s registration order for the Cancer Council and cl 3(5) treats the order as conclusive evidence that requirements have been complied with. That interacts with general principles of administrative law, but the statute is explicit that in these specific matters judicial challenge is precluded.

Overall effect

• The Act is not a stand-alone instrument. Its practical application and many operational aspects (employment, investment, public health administration, corporate conversion, taxation of gifts) are definitionalised in or contingent upon other statutes. Section 21A is explicit: Chapter 10 of the Health Services Act, as extended, prevails over the Cancer Institute Act where inconsistent. That statutory hierarchy will be critical where administrative rules in the Health Services Act conflict with Cancer Institute procedures.

The Act text includes embedded marginal amendment notes which indicate the legislative changes up to the versions cited in the provided text. The source identifies specific amendments and repeals in several years. The following summaries are drawn from the amendment notes and schedule notes contained in the statutory text provided.

Early amendments and enactment notes

• The Act originally enacted as Cancer Institute (NSW) Act 2003; the marginal notes identify amendments across multiple subsequent Acts.

2003

• Section 6 has an amendment note: “s 6: Am 2003 No 82, Sch 2.1.” This indicates that s 6 (Guiding principles) was amended by the 2003 amendment Act in Schedule 2.1.

2005

• Schedule 3 is annotated “sch 3: Am 2005 No 64, Sch 2.4. Rep 2006 No 58, Sch 4. Ins 2012 No 78, Sch 1 [11].” This summary indicates that Schedule 3 was inserted or amended in 2005 with later repeals and insertions. Schedule 2 cl 3 contains an editorial note indicating the registration date under sch 2 cl 3(1) was specified as 30.9.2005 in Gazette No 119 of 28.9.2005, p 7597.

2006

• Section 10 shows an amendment note: “s 10: Am 2006 No 2, Sch 4.6 [1]; 2012 No 78, Sch 1 [3] [4].” This indicates 2006 changes (Sch 4.6) to s 10 and later 2012 changes.
• Several provisions are annotated as repealed by a 2006 Act: e.g., s 11: “s 11: Rep 2006 No 2, Sch 4.6 [2]. Ins 2012 No 78, Sch 1 [5].” Section 28 is annotated as “Rep 2006 No 58, Sch 4.” Schedule 3 entries reference a 2006 repeal as well.

2012

• A substantive amendment series in 2012 is indicated by multiple notes: s 3: “Am 2012 No 78, Sch 1 [1]”; s 8: “s 8: Am 2012 No 78, Sch 1 [2]”; s 12: “s 12: Am 2006 No 2, Sch 4.6 [3]; 2012 No 78, Sch 1 [6]; 2015 No 58, Sch 3.13 [2] [3].” Section 11 was reinserted or amended by the 2012 Act (ins 2012 No 78, Sch 1 [5]) after a prior repeal. Schedule 1 has multiple amendment notes: “sch 1: Am 2012 No 78, Sch 1 [10]; 2015 No 58, Sch 3.13 [4].”

2015

• Section 3 and sections 12, 13 and others carry notes indicating adjustments in 2015: e.g., s 3: “...; 2015 No 58, Sch 3.13 [1].” s 12 references 2015 No 58 Sch 3.13 [2] [3]. s 13 has the note “s 13: Am 2015 No 58, Sch 3.13 [2] [3].” Schedule 1 carried a 2015 amendment to cl 4 (term of office) (sch 1 notes).

2018

• Section 18 shows an amendment note: “s 18: Am 2018 No 70, Sch 3.8.” This indicates investment provisions were updated in 2018, reflecting changes tied to the Government Sector Finance Act 2018.

Repeals and insertions

• Section 21 was repealed by 2012 No 78 Sch 1 [7] (s 21: Rep 2012 No 78, Sch 1 [7]). Section 21A was inserted by 2012 No 78 Sch 1 [8] (s 21A: Ins 2012 No 78, Sch 1 [8]). Section 28 was repealed in 2006 (s 28: Rep 2006 No 58, Sch 4). Schedule 3 has a record of being amended in 2005, repealed in 2006 and reinserted in 2012 (sch 3 notes).

Transitional provisions

• Schedule 3 contains savings, transitional and other provisions consequential on the Act and its amendments, and it is annotated as having been amended, repealed and reinserted across various years (sch 3 notes). Part 2 of Schedule 3 contains provisions consequent on the 2012 Amendment Act, including staff transfers and saving of Board appointments (sch 3 Part 2 cl 2-4).

Cancer Council conversion timing

• Schedule 2 cl 3 contains a Gazette editorial note specifying the registration date: the day specified under cl 3(1) is 30.9.2005 (Gazette No 119 of 28.9.2005, p 7597). That marks the operational conversion date for the Cancer Council under the sch 2 mechanism.

How to treat these amendment notes

• The marginal notes attached to each section in the provided text are the source’s statement of amendment history. They identify the amending Acts and the schedule or clause numbers that effected change. For detailed legislative history beyond those notations , for example, full text of amending Acts or explanatory memoranda , the statutory note references must be read against the public statutes and parliamentary materials. The Act as provided includes the annotation trail required to identify where substantive amendments occurred and which provisions have been repealed or inserted at those cited dates.

The text of the Act supplied does not list or summarise judicial decisions interpreting the Act. The statutory source itself is silent about case law. Two relevant statutory features in the text bear on litigation risk and reviewability:

Non-justiciability of certain Ministerial orders

• Schedule 2 cl 3(4) explicitly states that an order under cl 3 specifying the Cancer Council registration date “cannot be challenged, reviewed or called into question in any proceedings before any court or tribunal.” Clause 3(5) also provides that such an order is conclusive evidence in any proceedings that the requirements of the Schedule concerning registration have been complied with. These are express statutory bars on judicial review and evidentiary conclusive findings for that specific administrative act.

Other finality and immunity provisions

• The Act provides a statutory immunity from personal liability for actions or omissions done in good faith for the purposes of executing the Act (s 22). While not a bar to litigation in the abstract, s 22 restricts the personal civil-claim exposure of Board members, staff, committees, and other specified actors where the acts were done in good faith.

Absence of listed cases and offences

• Unlike some statutes, the text does not contain a schedule of cases, nor does it record or cite any judicial decisions. Also, the Act does not create specific penal or criminal provisions within the provided text that commonly generate litigation about enforcement; remedies are administrative (removal, approvals, directions) and subject to political or contractual mechanisms. If courts have considered the Act, that information would be external to the statutory text and must be sought in case law databases.

Practical litigation considerations from the Act

• Given the cl 3(4) bar on challenge to the Minister’s registration order, litigation risk in relation to that particular decision is legislatively reduced. More generally, disputes over the Institute’s actions are likely to involve administrative law issues, contractual disputes (contracts entered by the Institute are deemed Public Service contracts for Constitution Act purposes, s 17(2)), and questions about conflicts of interest and fiduciary duties of Board members. The statutory immunity in s 22 and the Ministerial removal powers substantially shape the contours of any litigation strategy and cause of action by limiting personal liability and conferring substantial executive control.

If litigation history or judicial interpretation is required beyond the statutory text, users should consult case law databases and decisions of NSW and federal courts and tribunals to identify any authoritative judgments that have construed the statutory provisions. The Act as supplied contains no internal litigation history to report.

The Act contains a number of features that create practical risks, decision points, compliance frictions and interactions that stakeholders should note. The following are specific, concrete mechanisms and consequences grounded in the statutory language.

Ministerial control and removal without cause

• The Governor (and effectively the Executive) may remove any member or all members for any reason or no reason and appoint an administrator (s 11(1)). Schedule 1 cl 6(2) allows the Minister to remove an appointed member at any time for any or no reason and without notice. Consequence: Board independence is constrained by explicit statutory removal powers and administrators can assume Board functions; appointments are not insulated by contractual protection against removal or entitlement to compensation (sch 1 cl 10).

Limits on employment and delegation structural tension

• The Act says the Cancer Institute cannot employ staff under this Act (s 12(4)). The Act then contemplates staff being employed under Chapter 9 of the Health Services Act to enable the Institute to exercise its functions (s 12(4) note). At the same time, the Institute may delegate functions to “members of staff of the Cancer Institute” (s 20(1)). This creates an operational dependency: delegation presumes staff will be in place via another statutory employment regime. Practical implication: governance, HR and industrial arrangements must be coordinated with the Health Services Act employment framework; the Institute cannot independently set employment terms in the Act itself.

Ministerial approval for land dealings and by-laws

• The Institute may acquire and dispose of land but must do so only with the Minister’s approval (s 15(2)). By-laws require Minister approval (s 19(1)). Practical implication: strategic property transactions, leasing, sale or long-term dedication require Minister sign-off, which may delay or condition transactions and requires early engagement with the Minister’s office.

Information requests constrained by Secretary consent

• The Institute may request information from any person or body (s 13(1)), but if the request is to the Ministry of Health or a public health organisation the request must be complied with only if the Secretary consents (s 13(2)). Operational implication: data collection from public-system partners is contingent on Secretary approval, which is a gating mechanism that can limit the Institute’s independent access to public health data.

Conflict disclosure and public inspection of disclosures

• Board members must disclose conflicts and particulars are recorded in a book that must be open at all reasonable hours for inspection on payment of a fee determined by the Board (sch 1 cl 8(3)). This creates transparency obligations but also privacy and commercial confidentiality issues for disclosed interests. Practical consequence: members and counterparties should be aware that disclosures may be publicly inspectable and that the Board sets the inspection fee.

Finality of Ministerial orders re Cancer Council

• Schedule 2 cl 3(4) bars challenge to the Minister’s order specifying the Cancer Council registration date and cl 3(5) deems the order conclusive evidence of compliance with the Schedule. This statutory finality prevents judicial review in that specific context and limits legal remedies regarding that administrative act.

Good-faith immunity

• Section 22 immunises persons acting or omitting acts in good faith under the Act from personal action, liability, claim or demand. While this protects officials and staff, it may limit the legal avenues available to third parties seeking redress for negligent or otherwise injurious administrative acts so long as the actor’s conduct is plausibly characterised as in good faith.

Delegation limits and non-delegable functions

• The Institute may delegate to staff any of its functions other than the power to make by-laws and the power to delegate (s 20(1)). It cannot delegate the whole of its functions (s 20(3)). Practical implication: some governance decisions must remain with the Board or a delegated officer and certain legal acts (by-laws) must be done at the Institute level with Minister approval.

Contracts deemed Public Service contracts

• Contracts and agreements entered by the Institute are taken to be contracts for or on account of the Public Service of NSW for the purposes of the Constitution Act 1902 (s 17(2)). This affects procurement, liability, and perhaps industrial relations and constitutional considerations , counterparties should be aware their contracting counterparty is a statutory corporation contracting in a public-service capacity.

No express penalty regime in the Act

• The Act does not set out civil or criminal penalties for non-compliance by third parties or for breaches of statutory duties in the text provided. Enforcement is primarily administrative. Parties looking for statutory remedies or sanctions for malpractice that the Institute might exercise will not find express infringement fines or criminal offences in this text.

Interactional complexity with other statutes

• Section 21A makes Chapter 10 of the Health Services Act 1997 extend to the Institute and prevail to the extent of inconsistency (s 21A(1)-(2)). This means administrative rules and governance obligations under the Health Services Act may override conflicting Institute provisions. Operational risk: stakeholders must consult both Acts when interpreting obligations, especially regarding staffing, reporting and administration.

Fundraising registers and tax exemptions

• The Institute must keep publicly available registers of bodies conducting fundraising activities (s 12(2)(r); s 6(h) calls for publicly available information). Gifts and bequests are exempt from the Duties Act (s 16(4)). Practical consequence: donors may benefit from exemptions; fundraising bodies may be subject to additional public transparency requirements.

Taken together, these features create a governance model with substantial executive decision points, procedural transparency obligations, and statutory delegations and immunities. Each of these “gotchas” creates practical compliance and legal visibility issues that should be incorporated into operational and risk frameworks for any entity contracting with or participating in Institute processes.

This section sets out concrete, source-grounded steps organisations and individuals should follow to comply with the Act’s requirements and to minimise legal and operational risk.

For the Board and appointed members

• Expect Ministerial appointment and removal: accept that appointment is by the Minister (s 8(1)(a)) and removal can occur without cause (sch 1 cl 6(2); s 11(1)). Ensure appointments, terms and reappointments are managed administratively and that members understand no compensation is payable on removal or non-reappointment (sch 1 cl 10).
• Maintain robust conflict disclosure procedures: comply with Schedule 1 cl 8 by disclosing direct or indirect pecuniary and other interests as soon as the facts are known, ensure particulars are recorded in the disclosure book, and comply with non-participation rules unless the Minister or Board determines otherwise (sch 1 cl 8(1)-(5)). Set sensible procedures for managing inspection requests to the disclosure book and set a transparently determined fee (sch 1 cl 8(3)).
• Follow meeting procedure, quorum and voting rules: hold meetings consistent with the Board’s by-laws and the Act; quorum is a majority of members (sch 1 cl 12), the Chair presides with a casting vote (sch 1 cl 13), and decisions are by majority (sch 1 cl 14). Record resolutions transacted outside meetings as required (sch 1 cl 15).

For the Chief Cancer Officer and staff

• Confirm employment classification under the Health Services Act: determine whether the Chief Cancer Officer is an “executive position” under Part 3 of Chapter 9 of the Health Services Act; if so employment and appointment procedures under that Act apply; if not, appointment is by the Minister and employment under Part 1 of Chapter 9 during the office term (s 10(2)-(2A)). Ensure HR practices align with the Health Services Act because the Institute cannot employ staff under this Act itself (s 12(4) note).
• Implement delegation and delegation records: when delegating functions to staff, comply with s 20(1) by documenting delegations and ensuring they do not include the power of delegation itself or by-law making powers; retain records of delegations and any Ministerial directions concerning delegations (s 20(2)).

For property, investment and fundraising actions

• Seek Ministerial approval for land transactions: before acquiring or disposing of land by sale, lease, mortgage or other means, obtain the Minister’s approval (s 15(2)). Use s 15(3) if a proposed disposition conflicts with Crown grant provisions and obtain the Minister’s approval under s 15(3) if necessary.
• Observe investment rules: if the Institute is a GSF agency, investments must comply with Part 6 of the Government Sector Finance Act 2018; if not, invest only in ways authorised for trust funds or with Minister/Treasurer concurrence (s 18(1)). Maintain compliance records and trust-term documents where investments are subject to trust terms (s 18(3)).
• Handle gifts and bequests with the conditions agreed: ensure legal documentation records any conditions attached to gifts or bequests and the Institute’s agreement to those conditions; the Institute may retain securities and pay calls within limited periods (s 16(1)-(3)). Maintain records to support Duties Act exemptions (s 16(4)).

For information requests and data handling

• Follow Secretary consent process: when requesting information from the Ministry of Health or public health organisations, obtain Secretary consent before treating the request as enforceable (s 13(2)). Document consent and the scope of permitted information transfer. For requests to non-government bodies, ensure requests are lawful and respect privacy and other statutory obligations, though s 13(1) gives the Institute power to request information generally.
• Meet annual reporting obligations: prepare and provide the annual report to the Minister within four months after the end of each financial year, including required content (outcomes from initiatives; incidence, mortality and survival trends; overview of research and philanthropic activities) and support Parliamentary tabling (s 14(1), (3)-(4)). Put governance processes in place to gather necessary data across functions.

For by-laws, committees and ethics oversight

• Obtain Ministerial approval for by-laws: before making by-laws under s 19(1), secure the Minister’s approval and ensure they are not inconsistent with the Act or regulations (s 19(1)). Keep by-laws and authentication records (s 19(3)).
• Form required committees and document advice roles: establish the Ethics Committee, Clinical Services Advisory Committee, Research Advisory Committee, Quality and Clinical Effectiveness Advisory Committee and any other appropriate committees as required by s 9(1). Document committee membership, functions, minutes and advice to the Board in accordance with s 9(2)-(4).

For contracting and procurement

• Treat contracts as public-service contracts: record that contracts entered under s 17 are taken to be contracts for or on account of the Public Service of NSW for Constitution Act purposes (s 17(2)). Align procurement and contract management with public-sector processes and the Institute’s by-laws and Ministerial directions.
• Ensure adequate approval workflows: for any contract involving land, property or delegations that may intersect with Ministerial controls, build approval steps into contract timetables.

For interactions with the Cancer Council conversion (if applicable)

• Follow sch 2 procedural steps: if engaged with the Cancer Council company conversion, note that the Minister specified the registration date and must provide ASIC with a copy of the order (sch 2 cl 3(1), (3)). Be aware of cl 3(4)-(5) finality if advising on legal challenges concerning the registration date.

Records, disclosure, and openness

• Keep and publish required registers: maintain publicly available registers for bodies involved in research and for bodies conducting fund raising activities where required by s 12(2)(b) and (r). Maintain a public-facing approach consistent with s 6(h) and the Institute’s transparency obligations.
• Manage disclosure book access: when the disclosure book is inspected as permitted by sch 1 cl 8(3), charge the Board-determined fee and ensure inspection does not breach confidentiality or privacy laws; coordinate with legal and privacy officers on redaction or access procedures.

Operational risk management and legal advice

• Where the Secretary’s consent, Ministerial approval, or Health Services Act employment arrangements are implicated, obtain formal legal advice and record approvals to create audit trails. Given the Act’s administrative levers and immunity provisions, robust administrative records are the principal means to demonstrate compliance and to respond to any political or legal scrutiny.

Following these steps grounded in the statutory provisions will position the Institute, Board members, staff and counterparties to comply with statutory duties, manage approval requirements and document compliance with reporting and transparency obligations.